Membership

RFP, CGN and CGA Opportunities

The Alliance is a community dedicated to connecting healthcare education professionals to promote best practices that improve patient care. To help achieve this, we collect information on research proposals and grants offered through other healthcare-related organizations. If your company is interested in posting a request for grant applications, please contact the Alliance Business Office at acehp@acehp.org


Biogen

Biogen considers requests for independent medical education activities within the disease areas listed below. As areas of interest may change periodically, please consult the Biogen Grants and Giving website (https://grantsandgiving.biogen.com/) for the most up to date information. Please note that the submission and review process for international funding opportunities may differ.

  • Alzheimer’s Disease
  • Amyotrophic Lateral Sclerosis
  • Lupus
  • Multiple Sclerosis
  • Ophthalmology
  • Parkinson’s Disease
  • Spinal Muscular Atrophy

For additional information on the Biogen grant submission process, please visit our website.


Bristol-Myers Squibb

Bristol-Myers Squibb accepts funding requests within the following therapeutic areas of interest. As areas of interest and funding consideration may change periodically, please consult this website frequently. Please note that international funding opportunities may differ.

  • Cardiovascular
  • Immunoscience
  • Oncology
  • Virology
  • Genetically Defined / Rare Diseases

View Request for Proposals / for Education


Daiichi-Sankyo

Request for Proposal (RFP):  Molecular Diagnostics and Emerging Targeted Cancer Therapies for HER2+ Metastatic Breast Cancer: from the clinical value and impact of testing to the utilization of emerging targeted therapies to provide the optimal outcomes to patients with cancer

Posting Date: Week of August 7, 2020

Therapeutic focus

  • HER2+ Metastatic Breast Cancer 
Recommended Learning Format
  • Daiichi Sankyo welcomes all tactical recommendations that demonstrate a reduction in ongoing clinical and learning gaps. During this current time, Daiichi Sankyo may provide a preferential review to virtual and/or digitally interactive certified program(s) that meet (not adds to) the overextended demands clinicians face during COVID-19. 
Recommended Learning Target
  • Global/world-wide academic and community medical oncologists, pathologists, oncology nurses, pharmacists, and other clinical oncology team members, to include regions in Africa, Asia, Australia, Europe, North America (U.S. included), and South America   

Phase 1 Due: August 21, 2020
(Daiichi Sankyo communicates phase 1 decision on September 4)
Phase 2 Due: September 18, 2020
Final grant decision communicated: October 9, 2020
Expected launch date: Between October and December 2020 in order to incorporate all fair/balanced current and emerging information through 2020, inclusive of recent evidence reported at annual oncology conferences (i.e. ASCO, AACR, ESMO, etc.)
 
The Process for the Daiichi Sankyo RFP Submission
Phase 1: Initial Executive Summary to include one-to-two page(s) of a summarized gap analysis and description of the educational design, tactic, implementation, and outcomes plan to be submitted to OGE-CME@dsi.com with the subject line “2020 RFP 20002 [& your personalized title]”
Phase 2: If selected to move forward, you will be invited to expand upon your initial Executive Summary by submitting a complete Grant Request to DSI.com, under “Responsibility,” and “CME Grants,” choosing the appropriate RFP dropdown item when starting the submission process, and then titling your grant as “2020 RFP 20002 [& your personalized title]”
Daiichi Sankyo welcomes all accredited or accredited-partnered educational providers to respond to this request. We ask that educational providers only submit one response to each RFP. All submissions will be reviewed in compliance with our Standard Operating Procedures and policies, impartially without any preset grant decision(s) made at the release of this RFP.

Questions regarding this RFP can be submitted to OGE-CME@dsi.com  

Request for Proposal (RFP):  Molecular Diagnostics and Emerging Targeted Cancer Therapies for HER2+ Metastatic Gastric and/or Colorectal Cancers: from the clinical value and impact of testing to the utilization of emerging targeted therapies to provide the optimal outcomes to patients with cancer

Posting Date: Week of August 7, 2020

Therapeutic focus

  • HER2+ metastatic Gastric and/or Colorectal Cancers 
Recommended Learning Format
  • Daiichi Sankyo welcomes all tactical recommendations that demonstrate a reduction in ongoing clinical and learning gaps. During this current time, Daiichi Sankyo may provide a preferential review to virtual and/or digitally interactive certified program(s) that meet (not adds to) the overextended demands clinicians face during COVID-19. 
Recommended Learning Target
  • Global/world-wide academic and community medical oncologists, pathologists, oncology nurses, pharmacists, and other clinical oncology team members, to include regions in Africa, Asia, Australia, Europe, North America (U.S. included), and South America   

Phase 1 Due: August 21, 2020
(Daiichi Sankyo communicates phase 1 decision on September 4)
Phase 2 Due: September 18, 2020
Final grant decision communicated: October 9, 2020
Expected launch date: Between October and December 2020 in order to incorporate all fair/balanced current and emerging information through 2020, inclusive of recent evidence reported at annual oncology conferences (i.e. ASCO, AACR, ESMO, etc.)
 
The Process for the Daiichi Sankyo RFP Submission
 Phase 1: Initial Executive Summary to include one-to-two page(s) of a summarized gap analysis and description of the educational design, tactic, implementation, and outcomes plan to be submitted to OGE-CME@dsi.com with the subject line “2020 RFP 20002 [& your personalized title]”
 Phase 2: If selected to move forward, you will be invited to expand upon your initial Executive Summary by submitting a complete Grant Request to DSI.com, under “Responsibility,” and “CME Grants,” choosing the appropriate RFP dropdown item when starting the submission process, and then titling your grant as “2020 RFP 20002 [& your personalized title]”
Daiichi Sankyo welcomes all accredited or accredited-partnered educational providers to respond to this request. We ask that educational providers only submit one response to each RFP. All submissions will be reviewed in compliance with our Standard Operating Procedures and policies, impartially without any preset grant decision(s) made at the release of this RFP.

Questions regarding this RFP can be submitted to OGE-CME@dsi.com  

Request for Proposal (RFP):  Molecular Diagnostics and Emerging Targeted Cancer Therapies for HER2+ and HER2 Mutant Metastatic NSCLC: from the clinical value and impact of testing to the utilization of emerging targeted therapies to provide the optimal outcomes to patients with cancer

Posting Date: Week of August 7, 2020

Therapeutic focus

  • HER2+ and HER2 mutant metastatic Non-Small Cell Lung Cancer (NSCLC) 
Recommended Learning Format
  • Daiichi Sankyo welcomes all tactical recommendations that demonstrate a reduction in ongoing clinical and learning gaps. During this current time, Daiichi Sankyo may provide a preferential review to virtual and/or digitally interactive certified program(s) that meet (not adds to) the overextended demands clinicians face during COVID-19. 
Recommended Learning Target
  • Global/world-wide academic and community medical oncologists, pathologists, oncology nurses, pharmacists, and other clinical oncology team members, to include regions in Africa, Asia, Australia, Europe, North America (U.S. included), and South America   

Phase 1 Due: August 21, 2020
(Daiichi Sankyo communicates phase 1 decision on September 4)
Phase 2 Due: September 18, 2020
Final grant decision communicated: October 9, 2020
Expected launch date: Between October and December 2020 in order to incorporate all fair/balanced current and emerging information through 2020, inclusive of recent evidence reported at annual oncology conferences (i.e. ASCO, AACR, ESMO, etc.)
 
The Process for the Daiichi Sankyo RFP Submission
 Phase 1: Initial Executive Summary to include one-to-two page(s) of a summarized gap analysis and description of the educational design, tactic, implementation, and outcomes plan to be submitted to OGE-CME@dsi.com with the subject line “2020 RFP 20002 [& your personalized title]”
 Phase 2: If selected to move forward, you will be invited to expand upon your initial Executive Summary by submitting a complete Grant Request to DSI.com, under “Responsibility,” and “CME Grants,” choosing the appropriate RFP dropdown item when starting the submission process, and then titling your grant as “2020 RFP 20002 [& your personalized title]”
Daiichi Sankyo welcomes all accredited or accredited-partnered educational providers to respond to this request. We ask that educational providers only submit one response to each RFP. All submissions will be reviewed in compliance with our Standard Operating Procedures and policies, impartially without any preset grant decision(s) made at the release of this RFP.

Questions regarding this RFP can be submitted to OGE-CME@dsi.com  

Request for Proposal (RFP):  Identifying and Managing Interstitial Lung Disease (ILD) and Pneumonitis in Patients on Cancer Therapy:  from the clinical value and impact of testing to the utilization of emerging targeted therapies to provide the optimal outcomes to patients with cancer

Posting Date: Week of August 7, 2020

Therapeutic focus

  • “General oncology” grants queue, pan-tumor educational initiative, to include HER2+ metastatic Breast Cancer, HER2+ metastatic Gastric Cancer, HER2+ metastatic Colorectal Cancer, and HER2+ & HER2 mutant metastatic Non-Small Cell Lung Cancers 
Recommended Learning Format
  • Daiichi Sankyo welcomes all tactical recommendations that demonstrate a reduction in ongoing clinical and learning gaps. During this current time, Daiichi Sankyo may provide a preferential review to virtual and/or digitally interactive certified program(s) that meet (not adds to) the overextended demands clinicians face during COVID-19. 
Recommended Learning Target
  • Global/world-wide academic and community medical oncologists, pathologists, oncology nurses, pharmacists, and other clinical oncology team members, to include regions in Africa, Asia, Australia, Europe, North America (U.S. included), and South America   

Phase 1 Due: August 21, 2020
(Daiichi Sankyo communicates phase 1 decision on September 4)
Phase 2 Due: September 18, 2020
Final grant decision communicated: October 9, 2020
Expected launch date: Between October and December 2020 in order to incorporate all fair/balanced current and emerging information through 2020, inclusive of recent evidence reported at annual oncology conferences (i.e. ASCO, AACR, ESMO, etc.)
 
The Process for the Daiichi Sankyo RFP Submission
 Phase 1: Initial Executive Summary to include one-to-two page(s) of a summarized gap analysis and description of the educational design, tactic, implementation, and outcomes plan to be submitted to OGE-CME@dsi.com with the subject line “2020 RFP 20002 [& your personalized title]”
 Phase 2: If selected to move forward, you will be invited to expand upon your initial Executive Summary by submitting a complete Grant Request to DSI.com, under “Responsibility,” and “CME Grants,” choosing the appropriate RFP dropdown item when starting the submission process, and then titling your grant as “2020 RFP 20002 [& your personalized title]”
Daiichi Sankyo welcomes all accredited or accredited-partnered educational providers to respond to this request. We ask that educational providers only submit one response to each RFP. All submissions will be reviewed in compliance with our Standard Operating Procedures and policies, impartially without any preset grant decision(s) made at the release of this RFP.

Questions regarding this RFP can be submitted to OGE-CME@dsi.com  

Eli Lilly and Company

LINK to Lilly Grant Office portal

Required Tool: Lilly RFP Budget Template

Therapeutic area of interest: Oncology

View Request for Proposal (RFP)


Genentech

Genentech is seeking to support learning initiatives that demonstrate a strategy that evolves knowledge-based medical education into a “healthcare Improvement” initiative that accelerates the awareness and application of evidence-based medicine, resulting in appropriate care for patients and relevant, measurable, clinical outcomes.

Therapeutic area(s) of interest:

  • Non-Malignant Blood Disorders

View Request for Proposal

Genentech is posting a Call for Grants (CGN) in support of IME activities in Early Non-Small Cell Lung Cancer.

2020 Independent Medical Education Call for Grant Notification

Genentech is posting a Call for Grants (CGN) in support of IME activities for Stroke.

2020 Independent Medical Education Call for Grant Notification 

Genentech is posting a Call for Grant Notification (CGN) for Prostate Cancer in support of IME activities.

2020 Independent Medical Education Call for Grant Notification

With increasing complications from COVID-19, we are extending the deadlines associated with the Call for Grant Notification (CGN) in support of education in hepatocellular carcinoma for Hepatologists.

2020 Independent Medical Education Call for Grant Notification

Genentech is posting a Call for Grant Notification (CGN) for Disparities in Care (in TNBC, HCC, and general oncology) in support of IME activities. 

2020 Independent Medical Education Call for Grant Notification

Genentech is posting a Call for Grant Notification (CGN) on June 8, 2020 for General Oncology in support of IME activities.

2020 Independent Medical Education Call for Grant Notification

Genentech is posting a Call for Grant Notification (CGN) on June 12, 2020 for Hemophilia A and Acute Myeloid Leukemia (AML)  in support of IME activities.

2020 Independent Medical Education Call for Grant Notification


Indivior

Indivior supports independent medical education activities that provide for an increased understanding of scientific, clinical, or healthcare issues related to the company’s therapeutic areas of interest. 

Therapeutic areas of interest:

  • Opioid Use Disorder
  • Schizophrenia

To view open RFPs and complete details regarding grant submission, please visit the following site on a regular basis: grants.indivior.com


Jazz Pharmaceuticals

Jazz Pharmaceuticals is committed to improving patient outcomes and providing support in compliance with local regulations. The Jazz grant management system is currently accepting requests for medical education meetings, conferences, or symposia; medical center grand rounds lectures; fellowships; enduring medical education activities; and similar educational activities. In Europe and Rest of World (EU/RoW) the system is also accepting requests for goods (such as books, printing, materials, equipment) and services (such as administrative support, personnel, and tools).

Therapeutic areas of interest:

  • Neuroscience
  • Hematology/Oncology

View Request for Application (RFA)

Any questions can be directed to Jazz’s Medical Education Grants email address (mededgrant@jazzpharma.com). Please visit our website for additional information.


Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)

The Centers for Medicare & Medicaid Services (CMS) recognizes the benefits of measure development by external stakeholders with specific knowledge of clinician and patient perspectives and needs, such as clinical specialty societies, clinical professional organizations, patient advocacy organizations, educational institutions, independent research organizations, health systems, and other entities. 

On March 2, 2018, CMS published the “Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program” on Grants.gov. The purpose of this Funding Opportunity is to provide technical and funding assistance in the form of cooperative agreements to entities to develop, improve, update, or expand quality measures for use in the Quality Payment Program (QPP). 

For more information and to see the ‘Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program’ search by the title or the Catalog of Federal Domestic Assistance (CFDA) number, 93.986 on Grants.gov.


Novo Nordisk Inc.

Novo Nordisk is committed to supporting independent medical education programs that meet the educational needs of health care professionals (HCPs), patients and the community in ways that measurably grow their knowledge and skills to optimize patient or self care in the following therapeutic areas of interest:

  • Diabetes
  • Obesity

Please visit www.novonordiskgrants.com to apply for educational grants and access the IME Funding Document that provides information about educational priorities and available funding as well as current Request for Proposals (RFPs)/Call for Concept Proposals (CCPs) within these therapeutic areas.


Pfizer Independent Grants for Learning & Change (IGLC)

The mission of Pfizer Independent Grants for Learning & Change is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. The Joint Commission is an independent, not-for-profit organization that accredits and certifies nearly 21,000 health care organizations and programs in the United States. 

To view open RFPs and complete details, please visit this webpage.


Regeneron Pharmaceuticals

The Regeneron and Sanofi Genzyme Alliance seeks to close important medical educational gaps with regard to Advanced Basal Cell Carcinoma (BCC) through consideration of grant proposals for 2020-2021 independent medical education activities. Target audiences include Dermato-Oncologist, Oncologists, Dermatologists, Mohs surgeons (US Only), Pharmacists, Registered Nurses, and advanced-level practitioners via live and enduring distribution channels; please refer to the Request for Proposal for further details.


Shionogi Inc.

Shionogi accepts funding requests within the following therapeutic areas of interest.

  • Gram-negative multidrug-resistant infectious disease (ID)
  • Thrombocytopenia associated with chronic liver disease (CLD)
  • Opioid-induced Constipation (OIC)

The call for grants (CFG) opportunities will change on a quarterly basis.  Please consult our website to identify current opportunities.


TRC Healthcare

TRC Healthcare (TRC), the creators of Pharmacist’s Letter, is committed to helping clinicians and healthcare professionals make safe, effective, and efficient medication decisions.  In support of this mission, TRC is currently accepting submissions in response to the following Requests for Proposals (RFPs).

Proposals may be submitted by individuals or groups and are due December 13, 2019.  Please see the individual RFPs for more details.

To learn more about TRC, please visit https://trchealthcare.com/about-us/.